Sign up to get one-on-one HEMLIBRA support from your local Clinical Education Manager (CEM)

What can you expect from your CEM?

Whether you are considering HEMLIBRA or are already on treatment, CEMs are here to help answer all your HEMLIBRA questions—everything from how HEMLIBRA works to navigating the insurance coverage process.

Who is your CEM?

Your local CEM is part of your hemophilia community. While they don’t provide medical advice, they have years of nursing/clinical experience and are experts on HEMLIBRA.

Sign up below so your local CEM can reach out to you. Plus, you’ll receive a few emails with information on topics such as:

HEMLIBRA® (emicizumab-kxwh) Connect with a Clinical Education Manager icon
  • HEMLIBRA information and tips
  • Real stories from people taking HEMLIBRA
  • Insurance and financial assistance
  • Opportunities to connect with our team and our HEMLIBRA ambassadors
HEMLIBRA® (emicizumab-kxwh) Meet Julia Icon

“Our CEM gave a face and a name to the process of starting a new treatment. It’s nice to know that you have someone to provide you with answers about HEMLIBRA.”

— Julia, 57, Mother and Caregiver of Louis

It’s important to know that Clinical Education Managers do not provide medical advice. Please consult your doctor as needed.


Sign Up to Connect With Your Local CEM

All fields required*

You are living with:*
Are you currently on HEMLIBRA?*
The person you care for is living with:*
Is the person you care for currently on HEMLIBRA?*

By clicking "I Agree," I consent that the information I am providing may be used by Genentech, its successors, and its agents to keep me informed about products, patient support services, special offers, or other opportunities that may be of interest to me via mail and email. Genentech may also combine the information I provide with information about me from third parties to better match these offers with my interests. These materials may contain information that market or advertise Genentech products, goods, or services. I understand from time to time, Genentech's Online Privacy Policy may change and for the most recent version of the Online Privacy Policy, I should click here.

By clicking "I Agree," I am agreeing to Genentech's Online Privacy Policy and to the terms above, and I also affirm that I am at least eighteen (18) years of age or older.

You must click the "I Agree" button to complete your registration. If you do not agree to the terms above, you may exit out of this page and we invite you to explore other areas of the site without registering. You may return to this page at any time to register. Genentech understands protecting your personally identifiable information is very important. We do not share any personally identifiable information you give us with third parties for their own marketing use.

Have any questions about CEM support or signing up? Help is available in English and Spanish. Call 1-866-HEMLIBRA (1-866-436-5427), Monday to Friday, 9:00 AM–8:00 PM ET.

Clinical Education Managers do not provide medical advice; if you have questions about your medical condition, contact your healthcare provider.


Thanks for Signing Up!

 

We’re glad to provide you with resources

Thanks for joining. Be on the lookout for helpful emails from us soon. We look forward to being a resource for you to learn more about HEMLIBRA. If you have any immediate questions, please reach out to your local Clinical Education Manager.

Contact Your Local CEM

Who is your local CEM?

Please enter your ZIP Code below.

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.

These serious side effects include: 

  • Thrombotic microangiopathy (TMA), a condition involving blood clots and injury to small blood  vessels that may cause harm to your kidneys, brain, and other organs 
  • Blood clots (thrombotic events), which may form in blood vessels in your arm, leg, lung, or head  

Talk to your doctor about the signs and symptoms of these serious side effects, which can include: 

  • Confusion
  • Stomach, chest, or back pain
  • Weakness
  • Nausea or vomiting
  • Swelling, pain, or redness
  • Feeling sick or faint
  • Decreased urination
  • Swelling of arms and legs
  • Yellowing of skin and eyes
  • Eye pain, swelling, or trouble seeing
  • Fast heart rate
  • Numbness in your face
  • Headache
  • Shortness of breath
  • Coughing up blood

If you experience any of these symptoms during or after treatment with HEMLIBRA, get medical help right away. 

Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total. 

Your body may make antibodies against HEMLIBRA, which may stop HEMLIBRA from working properly. Contact your healthcare provider immediately if you notice that HEMLIBRA has stopped working for you (eg, increase in bleeds).

The most common side effects of HEMLIBRA include: injection site reactions (redness, tenderness, warmth, or itching at the site of injection), headache, and joint pain. These are not all of the possible side effects of HEMLIBRA. You can speak with your healthcare provider for more information.

What else should I know about HEMLIBRA?

See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.

  • Stop taking your prophylactic bypassing therapy the day before you start HEMLIBRA
  • You may continue taking your prophylactic factor VIII for the first week of HEMLIBRA

HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and create an inaccurate result. Speak with your healthcare provider about how this may affect your care. 

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Only use HEMLIBRA for the condition it was prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist.

Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.

Since HEMLIBRA was tested in males, there is no information on whether HEMLIBRA may impact your unborn baby or breast milk. Females who are able to become pregnant should use birth control during treatment.

Side effects may be reported to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see Important Safety Information, including Serious Side Effects, as well as the HEMLIBRA full Prescribing Information and Medication Guide.